Patients' characteristics according to molecular response to standard-dose imatinib therapy
| Characteristics . | Without MMR* (no. patients) . | With MMR (no. patients) . | P . |
|---|---|---|---|
| Quantitative features | |||
| Trough imatinib plasma levels† | 869.3 ± 427.5 (34) | 1452.1 ± 649.1 (34) | < .001 |
| Age, y | 50.7 ± 13.6 (34) | 51.7 ± 13.7 (34) | .76 |
| Sokal score | 0.9 ± 0.4 (32) | 1.0 ± 0.4 (33) | .33 |
| Qualitative features | |||
| Sex | .09 | ||
| Male | 70.6 (24) | 50.0 (17) | |
| Female | 29.4 (10) | 50.0 (17) | |
| Sokal risk group | .69 | ||
| Less than 0.8 | 44.1 (15) | 41.2 (14) | |
| 0.8-1.2 | 35.3 (12) | 32.4 (11) | |
| Greater than 1.2 | 14.7 (5) | 23.5 (8) | |
| Accelerated-phase CML | .58 | ||
| No | 76.5 (26) | 70.6 (24) | |
| Yes | 23.5 (8) | 29.4 (10) | |
| Interferon before imatinib | .62 | ||
| No | 44.1 (15) | 38.2 (13) | |
| Yes | 55.9 (19) | 61.8 (21) | |
| Daily imatinib dose | > .999 | ||
| 400 mg | 73.5 (25) | 73.5 (25) | |
| 600 mg | 26.5 (9) | 26.5 (9) |
| Characteristics . | Without MMR* (no. patients) . | With MMR (no. patients) . | P . |
|---|---|---|---|
| Quantitative features | |||
| Trough imatinib plasma levels† | 869.3 ± 427.5 (34) | 1452.1 ± 649.1 (34) | < .001 |
| Age, y | 50.7 ± 13.6 (34) | 51.7 ± 13.7 (34) | .76 |
| Sokal score | 0.9 ± 0.4 (32) | 1.0 ± 0.4 (33) | .33 |
| Qualitative features | |||
| Sex | .09 | ||
| Male | 70.6 (24) | 50.0 (17) | |
| Female | 29.4 (10) | 50.0 (17) | |
| Sokal risk group | .69 | ||
| Less than 0.8 | 44.1 (15) | 41.2 (14) | |
| 0.8-1.2 | 35.3 (12) | 32.4 (11) | |
| Greater than 1.2 | 14.7 (5) | 23.5 (8) | |
| Accelerated-phase CML | .58 | ||
| No | 76.5 (26) | 70.6 (24) | |
| Yes | 23.5 (8) | 29.4 (10) | |
| Interferon before imatinib | .62 | ||
| No | 44.1 (15) | 38.2 (13) | |
| Yes | 55.9 (19) | 61.8 (21) | |
| Daily imatinib dose | > .999 | ||
| 400 mg | 73.5 (25) | 73.5 (25) | |
| 600 mg | 26.5 (9) | 26.5 (9) |
Data are mean values (± SD) for quantitative features. Data are proportions (%) for qualitative features. P value was assessed using Student t test for quantitative variables and the chi-square test for qualitative variables
MMR indicates major molecular response (≥ 3 log reduction in BCR-ABL transcript levels). The main characteristics of the 68 patients with CML are classified into those with or without MMR.
Trough imatinib plasma levels are expressed in nanograms per milliliter (ng/mL).